# One-Page Executive Summary

**Last updated:** April 28, 2026

**Scope note:** This summary covers publicly visible / announced *in vivo* CAR-T developers, transactions and financings. It is not a complete inventory of stealth, academic or undisclosed programs.

## Bottom line

*In vivo* CAR-T is strategically important because it could address the biggest operating-model constraints of current CAR-T: individualized manufacturing, long treatment timelines, high cost, scalability limitations and access barriers.[FDA CAR-T class overview](https://www.fda.gov/safety/medical-product-safety-information/bcma-directed-or-cd19-directed-autologous-chimeric-antigen-receptor-car-t-cell-immunotherapies-fda) [Bot et al., Nature Reviews Drug Discovery](https://www.nature.com/articles/s41573-025-01291-5)

However, the field remains early. Recent M&A and partnership activity validates strategic interest in delivery-platform ownership, not broad clinical proof that *in vivo* CAR-T can replace *ex vivo* CAR-T.[Lilly/Kelonia](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-kelonia-therapeutics-advance-vivo-car-t-cell) [AbbVie/Capstan](https://news.abbvie.com/2025-06-30-AbbVie-to-Acquire-Capstan-Therapeutics%2C-Further-Strengthening-Commitment-to-Transforming-Patient-Care-in-Immunology) [Kite/Interius](https://investors.gilead.com/news/news-details/2025/Kite-to-Acquire-Interius-BioTherapeutics-to-Advance-In-Vivo-Platform/default.aspx) [EsoBiotec/AstraZeneca](https://www.esobiotec.com/esobiotec-to-be-acquired-by-astrazeneca-to-advance-cell-therapy-ambition/)

## Why now

Large pharma is moving early to secure exposure to *in vivo* cell-engineering platforms. Lilly's Kelonia acquisition, along with transactions involving Orna, Orbital, Capstan, Interius and EsoBiotec, suggests that buyers are paying for platform optionality before full clinical de-risking.[Lilly/Kelonia](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-kelonia-therapeutics-advance-vivo-car-t-cell) [Lilly/Orna](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies) [BMS/Orbital](https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Cell-Therapy-Portfolio-with-Acquisition-of-Orbital-Therapeutics/default.aspx) [AbbVie/Capstan](https://news.abbvie.com/2025-06-30-AbbVie-to-Acquire-Capstan-Therapeutics%2C-Further-Strengthening-Commitment-to-Transforming-Patient-Care-in-Immunology) [Kite/Interius](https://investors.gilead.com/news/news-details/2025/Kite-to-Acquire-Interius-BioTherapeutics-to-Advance-In-Vivo-Platform/default.aspx) [EsoBiotec/AstraZeneca](https://www.esobiotec.com/esobiotec-to-be-acquired-by-astrazeneca-to-advance-cell-therapy-ambition/)

## What matters most

1. Delivery specificity: Can the platform reach the right immune cells?[Bot et al., Nature Reviews Drug Discovery](https://www.nature.com/articles/s41573-025-01291-5)
2. Safety control: Can it avoid unacceptable off-target activity or immune toxicity?[FDA CAR-T class overview](https://www.fda.gov/safety/medical-product-safety-information/bcma-directed-or-cd19-directed-autologous-chimeric-antigen-receptor-car-t-cell-immunotherapies-fda)
3. Durability: Can in-body programming generate a meaningful therapeutic effect?[Li et al., PubMed](https://pubmed.ncbi.nlm.nih.gov/41928252/)
4. Conditioning burden: Can programs reduce or avoid lymphodepletion?[ClinicalTrials.gov NCT06917742](https://clinicaltrials.gov/study/NCT06917742) [ClinicalTrials.gov NCT07075185](https://clinicaltrials.gov/study/NCT07075185)
5. CMC scalability: Can the carrier be manufactured reproducibly at scale?[Bot et al., Nature Reviews Drug Discovery](https://www.nature.com/articles/s41573-025-01291-5)

## Strategic read-through

For pharma BD, *in vivo* CAR-T is a platform ownership opportunity.

For investors, value is likely to concentrate around delivery IP, immune-cell targeting and early human proof of mechanism.

For cell therapy incumbents, the near-term risk is strategic adjacency, not immediate commercial displacement.

## Watch points

The next major value inflection will come from human data showing selective targeting, manageable safety and either durable clinical benefit or repeatable dosing logic.[ClinicalTrials.gov NCT06917742](https://clinicaltrials.gov/study/NCT06917742) [ClinicalTrials.gov NCT07075185](https://clinicaltrials.gov/study/NCT07075185) [ClinicalTrials.gov NCT06539338](https://clinicaltrials.gov/study/NCT06539338)

## Selected source links

- [Lilly-Kelonia acquisition](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-kelonia-therapeutics-advance-vivo-car-t-cell)
- [AbbVie-Capstan acquisition](https://news.abbvie.com/2025-06-30-AbbVie-to-Acquire-Capstan-Therapeutics%2C-Further-Strengthening-Commitment-to-Transforming-Patient-Care-in-Immunology)
- [Kite-Interius acquisition](https://investors.gilead.com/news/news-details/2025/Kite-to-Acquire-Interius-BioTherapeutics-to-Advance-In-Vivo-Platform/default.aspx)
- [AstraZeneca-EsoBiotec acquisition](https://www.esobiotec.com/esobiotec-to-be-acquired-by-astrazeneca-to-advance-cell-therapy-ambition/)
- [BMS-Orbital acquisition](https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Cell-Therapy-Portfolio-with-Acquisition-of-Orbital-Therapeutics/default.aspx)
- [Lilly-Orna acquisition](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies)